SlideShare una empresa de Scribd logo
1 de 38
A  SEMINAR ONTRANSPORT  ACROSS  CACO-2 MONOLAYER GUIDED BY:BY: PATEL AKSHAY DR.MANISH PATEL               M.PHARM- 1(ph’ceutics)    (head of department)                 ROLL NO-05  Department of Pharmaceutics NOOTAN PHARMACY COLLEGE,VISNAGAR
content ,[object Object]
Intestinal absorption
Intestinal absorption models
Caco-2 monolayer
Caco-2 cell culture
Characterization of cell culture
Permeability assay
Permeability assay validation
Biological and analytical consideration
References,[object Object]
Intestinal Absorption: Biology Enterocite biology: Absorptive cells of intestine, function is terminal digestion and absorption of water and nutrients from the intestinal lumen. Polarised monolayer :          -Apical: microvilli face the interior of gut and increase 	the surface available for absorption by>1000 fold          -Basal: faces away from gut in contact with 	extracellular matrix.
Intestinal transport mechanism: Major types ,[object Object]
Transcellular: For most lipophilic drugs. This route involves either passive diffusion, carrier mediated or receptor mediated endocytosis,[object Object]
B: carrier mediated absorption at apical and basolateral membranes;
C: active efflux transporter on apical membrane, acting during absorption;
D: active efflux transporter on apical membrane, offering an additional route for drug clearance from the circulation;
E: intracellular metabolising enzymes localized inside the enterocytes, possibly combined with an active efflux transporter on apical and basolateral membranes. ,[object Object]
Intestinal absorption models 1Animal studies (Rat) - Very low throughput 2	Insitu intestinal models  - Very low throughput, expensive  	Human/rat primary intestinal cells -Short functional life, lose differentiation characteristics 3	Intestinal Epithelial Barrier Models ,[object Object]
HT 29 Cells: Colon carcinoma, cultured with galactose, express mucus producing goblet cells differenciation
Caco-2 Monolayer: Human colorectal adenocarcinoma Cell monolayer,[object Object]
Caco-2 cell monolayers spontaneously differentiate to express morphological and functional characteristics of mature small-intestinal enterocytes. The differentiated monolayers are polarized, with microvilli on the apical side.,[object Object]
Four times higher in transepithelial resistance compared to HT 29-cell monolayer
It expresses various drug metabolizing enzymes like, aminopeptidase, esterase, and sulfatase.,[object Object]
Dose not produce the mucus and unstirred water Observed in the intestine
No P-450 drug metabolizing enzyme activity has been reported
Expensive method
Time consuming as 21 days required for full cell differentiation
The necessity of LC / MS or HPLC for quantitation
Influence of P-gp is difficult to estimate,[object Object]
CaCO2 Culture media
Transport media
Characterization of cell monolayer Cellular Architecture (Microvilli, Junctional Complexes) Barrier Function ( Lucifer Yellow Permeability, TEER) Differentiation Markers (Alkaline Phosphate, Brush-Border Peptidases) Transporters (P-Glycoprotein, PepT1, Amino acid Transporter, glucose)
1.CELLULAR ARCHITECTURE 3 Days 21 Days
2.BARRIER FUNCTION ,[object Object],Measurement of the integrity of the caco-2 cell monolayer After washing the cell monolayer with 37°C tempered D-PBS (with Ca2+, Mg2+) (Dulbecco's Phosphate Buffered Saline), 1600 μl transport medium was added into the apical and 2800 μl transport medium was added into the basal compartment.  Allow for equilibrium for 60 min in the cell culture incubator.
4. The measurement chamber was tempered to 37°C with transport medium before the measurement. For the post-experimental TEER measurement, the withdrawn volume in the apical compartment was replaced with transport medium before TEER was measured. 5.Caco-2 monolayer with TEER values exceeding 250 Ωcm2 were used for transport experiments. 6. Background TEER may be recorded in wells without cell monolayers, and can be subtracted from the raw TEER values with cells.
B. Lucifer yellow (LY) rejection: Rinse the monolayer three times with 300 µL HBSS ( Hank’s buffer saline solution) in the apical wells and 28 mL in the feeder tray. Add 300 µL of LY solution to each well in the filter plate (Apical Template). Add 600 µL HBSS to each well of a 24-well receiver tray (Basolateral Template). Assemble the filter plate and 24-well receiver plate and incubate for 1–2 hours at 37°C. Remove the filter plate from the receiver plate and place the receiver plate into a fluorescent plate reader. Determine the LY fluorescence using an excitation wavelength of 425-430 nm and an emission wavelength of 515-520 nm, 540 nm.
	Calculate the percent of LY rejection across the cell monolayer by measuring fluorescence in the receiver plate as compared to an ‘equilibrium’ standard.The standard plate should consist of 4 wells with 600 µL HBSS (blank) and 4 wells with 200 µL LY (100 µg/mL) + 400 µL HBSS (equilibrium samples)Calculate the LY rejection using the following equation:                                           LY Rejection=100%-%LY Passage

Más contenido relacionado

La actualidad más candente

Bioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies
Dr. Kunal Chitnis
 
Comparision of dissolution profile
Comparision of dissolution profileComparision of dissolution profile
Comparision of dissolution profile
Ranjith Karanam
 
Scale up and post approval changes(supac)
Scale up and post approval changes(supac)Scale up and post approval changes(supac)
Scale up and post approval changes(supac)
bdvfgbdhg
 
Activation modulated drug delivery systems
Activation modulated drug delivery systemsActivation modulated drug delivery systems
Activation modulated drug delivery systems
Sonam Gandhi
 

La actualidad más candente (20)

Dissolution Testing Apparatus
Dissolution Testing ApparatusDissolution Testing Apparatus
Dissolution Testing Apparatus
 
Gastro retentive drug delivery system (GRDDS)
Gastro retentive drug delivery system (GRDDS)Gastro retentive drug delivery system (GRDDS)
Gastro retentive drug delivery system (GRDDS)
 
Bioequivalence Studies
Bioequivalence StudiesBioequivalence Studies
Bioequivalence Studies
 
Biowaivers
BiowaiversBiowaivers
Biowaivers
 
Higuchi plots for tablet dissolution
Higuchi plots for tablet dissolutionHiguchi plots for tablet dissolution
Higuchi plots for tablet dissolution
 
Drug interactions linked to transporters
Drug interactions linked to transportersDrug interactions linked to transporters
Drug interactions linked to transporters
 
permeability in vivo in vitro in situ.pptx
permeability in vivo in vitro in situ.pptxpermeability in vivo in vitro in situ.pptx
permeability in vivo in vitro in situ.pptx
 
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGN
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGNBIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGN
BIOPHARMACEUTIC CONSIDERATIONS IN DRUG PRODUCT DESIGN
 
Compendial methods of dissolution
Compendial methods of dissolutionCompendial methods of dissolution
Compendial methods of dissolution
 
Bioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence StudiesBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies
 
Sustained and controlled drug delivery system
Sustained and controlled drug delivery systemSustained and controlled drug delivery system
Sustained and controlled drug delivery system
 
alternative methods for dissolution.pptx
alternative methods for dissolution.pptxalternative methods for dissolution.pptx
alternative methods for dissolution.pptx
 
Comparision of dissolution profile
Comparision of dissolution profileComparision of dissolution profile
Comparision of dissolution profile
 
Similarity and difference factors of dissolution
Similarity and difference factors of dissolutionSimilarity and difference factors of dissolution
Similarity and difference factors of dissolution
 
In vitro Dissolution Testing Models
In vitro Dissolution Testing ModelsIn vitro Dissolution Testing Models
In vitro Dissolution Testing Models
 
Optimization in pharmaceutics & processing
Optimization in pharmaceutics & processingOptimization in pharmaceutics & processing
Optimization in pharmaceutics & processing
 
Scale up and post approval changes(supac)
Scale up and post approval changes(supac)Scale up and post approval changes(supac)
Scale up and post approval changes(supac)
 
Drug excipient interaction different method
Drug excipient interaction different methodDrug excipient interaction different method
Drug excipient interaction different method
 
Activation modulated drug delivery systems
Activation modulated drug delivery systemsActivation modulated drug delivery systems
Activation modulated drug delivery systems
 
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
 

Similar a Caco2 final ppt.

drug product performance invivo
 drug product performance invivo drug product performance invivo
drug product performance invivo
SUJITHA MARY
 
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
SSR Institute of International Journal of Life Sciences
 
LPDT_A_938857-2014
LPDT_A_938857-2014LPDT_A_938857-2014
LPDT_A_938857-2014
Mansi Shah
 
Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16
Todd Lusk
 
Final Mycrobacteriophages Article
Final Mycrobacteriophages ArticleFinal Mycrobacteriophages Article
Final Mycrobacteriophages Article
josearzon99
 

Similar a Caco2 final ppt. (20)

Caco-2 cell permeability assay for drug absorption
Caco-2 cell permeability assay for drug absorptionCaco-2 cell permeability assay for drug absorption
Caco-2 cell permeability assay for drug absorption
 
Caco 2 cell permeability assay
Caco 2 cell permeability assayCaco 2 cell permeability assay
Caco 2 cell permeability assay
 
Caco 2 Cell Permeability Assay
Caco 2 Cell Permeability AssayCaco 2 Cell Permeability Assay
Caco 2 Cell Permeability Assay
 
drug product performance invivo
 drug product performance invivo drug product performance invivo
drug product performance invivo
 
methods of determining drug absorption ppt
methods of determining drug absorption pptmethods of determining drug absorption ppt
methods of determining drug absorption ppt
 
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
Mechanistic Studies of in vitro Anti- Proliferative Potential of Arisaena int...
 
Presentation1 riya pfd 1q
Presentation1 riya pfd 1qPresentation1 riya pfd 1q
Presentation1 riya pfd 1q
 
LPDT_A_938857-2014
LPDT_A_938857-2014LPDT_A_938857-2014
LPDT_A_938857-2014
 
PDF Article Filtration
PDF Article FiltrationPDF Article Filtration
PDF Article Filtration
 
cell Viability princes
cell Viability  princescell Viability  princes
cell Viability princes
 
RADIOACTIVE PPT.pptx
RADIOACTIVE PPT.pptxRADIOACTIVE PPT.pptx
RADIOACTIVE PPT.pptx
 
ApoB Sequencing
ApoB SequencingApoB Sequencing
ApoB Sequencing
 
Mammalian project poster
Mammalian project posterMammalian project poster
Mammalian project poster
 
JBS 2010
JBS 2010JBS 2010
JBS 2010
 
131116 paper study 준섭
131116 paper study 준섭131116 paper study 준섭
131116 paper study 준섭
 
Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16Lusk_ceftriaxone_ASMS_2016_23May16
Lusk_ceftriaxone_ASMS_2016_23May16
 
Final Mycrobacteriophages Article
Final Mycrobacteriophages ArticleFinal Mycrobacteriophages Article
Final Mycrobacteriophages Article
 
131116 paper study 준섭
131116 paper study 준섭131116 paper study 준섭
131116 paper study 준섭
 
131116 paper study 준섭
131116 paper study 준섭131116 paper study 준섭
131116 paper study 준섭
 
Resealed erythrocytes
Resealed erythrocytesResealed erythrocytes
Resealed erythrocytes
 

Último

Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businessWhy Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
panagenda
 

Último (20)

Axa Assurance Maroc - Insurer Innovation Award 2024
Axa Assurance Maroc - Insurer Innovation Award 2024Axa Assurance Maroc - Insurer Innovation Award 2024
Axa Assurance Maroc - Insurer Innovation Award 2024
 
Understanding Discord NSFW Servers A Guide for Responsible Users.pdf
Understanding Discord NSFW Servers A Guide for Responsible Users.pdfUnderstanding Discord NSFW Servers A Guide for Responsible Users.pdf
Understanding Discord NSFW Servers A Guide for Responsible Users.pdf
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of Terraform
 
Artificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : UncertaintyArtificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : Uncertainty
 
GenAI Risks & Security Meetup 01052024.pdf
GenAI Risks & Security Meetup 01052024.pdfGenAI Risks & Security Meetup 01052024.pdf
GenAI Risks & Security Meetup 01052024.pdf
 
Data Cloud, More than a CDP by Matt Robison
Data Cloud, More than a CDP by Matt RobisonData Cloud, More than a CDP by Matt Robison
Data Cloud, More than a CDP by Matt Robison
 
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
 
Top 5 Benefits OF Using Muvi Live Paywall For Live Streams
Top 5 Benefits OF Using Muvi Live Paywall For Live StreamsTop 5 Benefits OF Using Muvi Live Paywall For Live Streams
Top 5 Benefits OF Using Muvi Live Paywall For Live Streams
 
Partners Life - Insurer Innovation Award 2024
Partners Life - Insurer Innovation Award 2024Partners Life - Insurer Innovation Award 2024
Partners Life - Insurer Innovation Award 2024
 
HTML Injection Attacks: Impact and Mitigation Strategies
HTML Injection Attacks: Impact and Mitigation StrategiesHTML Injection Attacks: Impact and Mitigation Strategies
HTML Injection Attacks: Impact and Mitigation Strategies
 
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
 
2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...
 
Manulife - Insurer Innovation Award 2024
Manulife - Insurer Innovation Award 2024Manulife - Insurer Innovation Award 2024
Manulife - Insurer Innovation Award 2024
 
Workshop - Best of Both Worlds_ Combine KG and Vector search for enhanced R...
Workshop - Best of Both Worlds_ Combine  KG and Vector search for  enhanced R...Workshop - Best of Both Worlds_ Combine  KG and Vector search for  enhanced R...
Workshop - Best of Both Worlds_ Combine KG and Vector search for enhanced R...
 
Deploy with confidence: VMware Cloud Foundation 5.1 on next gen Dell PowerEdg...
Deploy with confidence: VMware Cloud Foundation 5.1 on next gen Dell PowerEdg...Deploy with confidence: VMware Cloud Foundation 5.1 on next gen Dell PowerEdg...
Deploy with confidence: VMware Cloud Foundation 5.1 on next gen Dell PowerEdg...
 
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
 
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfBoost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdf
 
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businessWhy Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
 

Caco2 final ppt.

  • 1. A SEMINAR ONTRANSPORT ACROSS CACO-2 MONOLAYER GUIDED BY:BY: PATEL AKSHAY DR.MANISH PATEL M.PHARM- 1(ph’ceutics) (head of department) ROLL NO-05 Department of Pharmaceutics NOOTAN PHARMACY COLLEGE,VISNAGAR
  • 2.
  • 11.
  • 12. Intestinal Absorption: Biology Enterocite biology: Absorptive cells of intestine, function is terminal digestion and absorption of water and nutrients from the intestinal lumen. Polarised monolayer : -Apical: microvilli face the interior of gut and increase the surface available for absorption by>1000 fold -Basal: faces away from gut in contact with extracellular matrix.
  • 13.
  • 14.
  • 15. B: carrier mediated absorption at apical and basolateral membranes;
  • 16. C: active efflux transporter on apical membrane, acting during absorption;
  • 17. D: active efflux transporter on apical membrane, offering an additional route for drug clearance from the circulation;
  • 18.
  • 19.
  • 20. HT 29 Cells: Colon carcinoma, cultured with galactose, express mucus producing goblet cells differenciation
  • 21.
  • 22.
  • 23. Four times higher in transepithelial resistance compared to HT 29-cell monolayer
  • 24.
  • 25. Dose not produce the mucus and unstirred water Observed in the intestine
  • 26. No P-450 drug metabolizing enzyme activity has been reported
  • 28. Time consuming as 21 days required for full cell differentiation
  • 29. The necessity of LC / MS or HPLC for quantitation
  • 30.
  • 33. Characterization of cell monolayer Cellular Architecture (Microvilli, Junctional Complexes) Barrier Function ( Lucifer Yellow Permeability, TEER) Differentiation Markers (Alkaline Phosphate, Brush-Border Peptidases) Transporters (P-Glycoprotein, PepT1, Amino acid Transporter, glucose)
  • 35.
  • 36. 4. The measurement chamber was tempered to 37°C with transport medium before the measurement. For the post-experimental TEER measurement, the withdrawn volume in the apical compartment was replaced with transport medium before TEER was measured. 5.Caco-2 monolayer with TEER values exceeding 250 Ωcm2 were used for transport experiments. 6. Background TEER may be recorded in wells without cell monolayers, and can be subtracted from the raw TEER values with cells.
  • 37. B. Lucifer yellow (LY) rejection: Rinse the monolayer three times with 300 µL HBSS ( Hank’s buffer saline solution) in the apical wells and 28 mL in the feeder tray. Add 300 µL of LY solution to each well in the filter plate (Apical Template). Add 600 µL HBSS to each well of a 24-well receiver tray (Basolateral Template). Assemble the filter plate and 24-well receiver plate and incubate for 1–2 hours at 37°C. Remove the filter plate from the receiver plate and place the receiver plate into a fluorescent plate reader. Determine the LY fluorescence using an excitation wavelength of 425-430 nm and an emission wavelength of 515-520 nm, 540 nm.
  • 38. Calculate the percent of LY rejection across the cell monolayer by measuring fluorescence in the receiver plate as compared to an ‘equilibrium’ standard.The standard plate should consist of 4 wells with 600 µL HBSS (blank) and 4 wells with 200 µL LY (100 µg/mL) + 400 µL HBSS (equilibrium samples)Calculate the LY rejection using the following equation: LY Rejection=100%-%LY Passage
  • 39. Caco-2 Permeability Assay Procedure: After the desired cell growth period, remove the plate from the incubator and determine the electrical resistance for each well (as described above). Wash the monolayer, exchanging the volume three times using sterile HBSS, pH 7.4. After washing, remove the buffer from the filter plate and feeder tray. Transfer the filter plate to a 24-well transport analysis plate. To determine the rate of drug transport in the apical to basolateral direction, add 300 µL of the test compounds to the filter well. Drug concentrations typically ranging from 10 µm to 200 µm may be used (achieve desired concentration using HBSS, pH 7.4 or an alternative buffer of desired pH). Fill the wells of the 24-well receiver plate with 600 µL buffer. To determine the rate of drug transport in the basolateral to apical direction, add 600 µL of the test compounds to the 24-well receiver plate.
  • 40. Fill the filter wells (apical compartment) with 300 µL of buffer. Join the filter and receiver plates once all drugs and buffer have been added. Begin timing the experiment. Incubate at 37°C shaking at 60 rpm on a rotary shaker. Typical incubation times are 1 to 2 hours. For LC/MS analysis: At the end of the incubation, remove a fixed volume (typically 50–100 µL) directly from the apical and basolateral wells (using the basolateral access holes) or by disassembling the plates. Transfer the volume to a clean plate.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45. Biological pharmaceutical and analytical consideration
  • 47.
  • 48.
  • 49.
  • 50. 4) To study transport mechanism fro many compounds
  • 51. 5) In drug metabolism & toxicity effects.
  • 52.
  • 53.
  • 54.
  • 55.
  • 56. Good correlationbetween PAMPA & caco-2 data for a compound indicates a predominance ofpassive diffusion in its permeation.
  • 58. absorptive (active, paracellular ,gradient effect for acids) or
  • 59.
  • 60.
  • 61.
  • 62. MDCK cell lines originate from dogkidney.
  • 63.
  • 64.